Physician profile
Joseph Nassir
NPI 1255301024
$11,680.84
in general payments reported to CMS, 2019-2025
60 companies · $1,502 in 2025
The $1,502 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,063 · 2020: $1,678 · 2021: $1,832 · 2022: $1,236 · 2023: $1,692 · 2024: $1,679 · 2025: $1,502.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,872.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,872.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,828.58 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $1,402.90 | 2020-2025 | |
| Lilly USA, LLC | $710.30 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $597.00 | 2019-2025 | Evenity, Prolia, Otezla |
| Amarin Pharma, INC. | $538.27 | 2019-2021 | |
| Allergan, INC. | $500.64 | 2019-2020 | |
| Pfizer INC. | $460.20 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $447.90 | 2019-2024 | |
| Novo Nordisk INC | $441.83 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Janssen Pharmaceuticals, INC | $372.15 | 2019-2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $328.42 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Kowa Pharmaceuticals America, INC. | $324.38 | 2019-2023 | Seglentis, Livalo |
| Otsuka America Pharmaceutical, INC. | $299.42 | 2020-2023 | Rexulti |
| Horizon Therapeutics Plc | $278.54 | 2019-2022 | |
| Lundbeck LLC | $242.69 | 2020-2025 | Rexulti |
Show all 60 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Nassir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.